The use of nebivolol in patients with coexisting arterial hypertension and erectile disfunction Review article
Article Sidebar
Published:
Sep 30, 2015
Keywords:
cardiosexuology, nebivolol, arterial hypertension, erectile dysfunction
Main Article Content
Abstract
Arterial hypertension can be diagnosed in approximately 30% of Polish people. It is a wellknown fact that arterial hypertension leads to cardiovascular diseases. Lately, coexistence of arterial hypertension and erectile dysfunction in men arouse physicians’ interest. In Poland, erectile disorders are diagnosed in approximately 1.5 million men over 35 years of age. Erectile disorders can be caused both by arterial hypertension and, as a side effect, by hypotensive drugs. Nebivolol is one of the few hypotensive drugs not affecting sexual quality of life negatively and probably even affecting it positively.
Article Details
How to Cite
Wełnicki , M., Lew-Starowicz, Z., & Mamcarz , A. (2015). The use of nebivolol in patients with coexisting arterial hypertension and erectile disfunction. Medycyna Faktow (J EBM), 8(3(28), 20-23. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2291
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego.
2. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
3. Ayta I.A., McKinlay J.B., Krane R.J.: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-56.
4. Lew-Starowicz Z.: Raport seksualności Polaków. SMG/KRC, Warszawa 2002.
5. Dadej R.: Zaburzenia erekcji – fizjologia, epidemiologia, patofizjologia, diagnostyka i leczenie. Przew. Lek. 2001; 4(10): 106-111.
6. Lakin M.: Erectile Dysfunction. Cleveland Clinic. Center of Continuing Education.
7. Braun M., Wassmer G., Klotz T. et al.: Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int. J. Impot. Res 2000; 12: 305-311.
8. O’Donnell A.B., Arujo A.B., McKinlay J.B. et al.: The health of normally aging men: the Massachusetts Male Aging Study (1987–2004). Experimental Gerontology 2004; 39: 975-984.
9. Hodges L.D., Kirby M., Solanki J. et al.: The temporal relationship between erectile dysfunction and cardiovascular disease. Int. J. Clin. Pract. 2007; 61(12): 2019-2025.
10. Thompson I.M., Tangen C.M., Goodman P.J. et al.: Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294(23): 2996-3002.
11. Dong J.Y.: Erectile Dysfunction and Risk of Cardiovascular Disease. Meta-Analysis of Prospective Cohort Studies. J. Am. Coll. Cardiol. 2011; 58: 1378-1385.
12. Shiri R., Koskimaki J., Hakkinen J. et al.: Cardiovascular drug use and the incidence of erectile dysfunction. Int. J. Impot. Res. 2007; 19: 208-212.
13. Green J.S.A., Holden S.T.R., Ingram P. et al.: An investigation of erectile dysfunction in Gwent, Wales. BJU International 2001; 88: 551-553.
14. Baumhäkel M., Schlimmer N., Kratz M. et al.: Cardiovascular risk, drugs and erectile function – a systematic analysis. Int. J. Clin. Pract. 2011; 65(3): 289-298.
15. Martínez-Salamanca J.I., La Fuente J.M., Cardoso J. et al.: Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. J. Sex. Med. 2014; 11(5): 1182-1192.
16. Doumas M., Tsakiris A., Douma S. et al.: Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian. J. Androl. 2006; 8(2): 177-182.
17. Brixius K., Middeke M., Lichtenthal A. et al.: Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharmacol. Physiol. 2007; 34(4): 327-331.
18. Cordero A., Bertomeu-Martínez V., Mazón P. et al.: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc. Ther. 2010 Spring; 28(1): 15-22.
2. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
3. Ayta I.A., McKinlay J.B., Krane R.J.: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-56.
4. Lew-Starowicz Z.: Raport seksualności Polaków. SMG/KRC, Warszawa 2002.
5. Dadej R.: Zaburzenia erekcji – fizjologia, epidemiologia, patofizjologia, diagnostyka i leczenie. Przew. Lek. 2001; 4(10): 106-111.
6. Lakin M.: Erectile Dysfunction. Cleveland Clinic. Center of Continuing Education.
7. Braun M., Wassmer G., Klotz T. et al.: Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int. J. Impot. Res 2000; 12: 305-311.
8. O’Donnell A.B., Arujo A.B., McKinlay J.B. et al.: The health of normally aging men: the Massachusetts Male Aging Study (1987–2004). Experimental Gerontology 2004; 39: 975-984.
9. Hodges L.D., Kirby M., Solanki J. et al.: The temporal relationship between erectile dysfunction and cardiovascular disease. Int. J. Clin. Pract. 2007; 61(12): 2019-2025.
10. Thompson I.M., Tangen C.M., Goodman P.J. et al.: Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294(23): 2996-3002.
11. Dong J.Y.: Erectile Dysfunction and Risk of Cardiovascular Disease. Meta-Analysis of Prospective Cohort Studies. J. Am. Coll. Cardiol. 2011; 58: 1378-1385.
12. Shiri R., Koskimaki J., Hakkinen J. et al.: Cardiovascular drug use and the incidence of erectile dysfunction. Int. J. Impot. Res. 2007; 19: 208-212.
13. Green J.S.A., Holden S.T.R., Ingram P. et al.: An investigation of erectile dysfunction in Gwent, Wales. BJU International 2001; 88: 551-553.
14. Baumhäkel M., Schlimmer N., Kratz M. et al.: Cardiovascular risk, drugs and erectile function – a systematic analysis. Int. J. Clin. Pract. 2011; 65(3): 289-298.
15. Martínez-Salamanca J.I., La Fuente J.M., Cardoso J. et al.: Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. J. Sex. Med. 2014; 11(5): 1182-1192.
16. Doumas M., Tsakiris A., Douma S. et al.: Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian. J. Androl. 2006; 8(2): 177-182.
17. Brixius K., Middeke M., Lichtenthal A. et al.: Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharmacol. Physiol. 2007; 34(4): 327-331.
18. Cordero A., Bertomeu-Martínez V., Mazón P. et al.: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc. Ther. 2010 Spring; 28(1): 15-22.